PHARMACYCLICS GADOLITE MRI AGENT ENTERS PHASE III STUDIES
This article was originally published in The Gray Sheet
Executive Summary
PHARMACYCLICS GADOLITE MRI AGENT ENTERS PHASE III STUDIES for magnetic resonance imaging of the abdomen and pelvis, the firm announced Sept. 21. The multicenter trial, which is being conducted at 14 U.S. centers and one in Australia, will enroll 200 patients with "known or suspected abdominal and/or pelvic disease." To date, 15 patients have been enrolled in the trial; completion of the study is expected in early 1995, with a new drug application following in mid-1995.
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.